Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAST-AB trial of local antibiotic prophylaxis for breast implants in reconstructive surgery
2020-002459-40Phase 3Active
- Sponsor
- Rigshospitalet
- Start
- Jul 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefazolin, gentamicin and vancomycin in breast cancer (2 arms), sponsored by Rigshospitalet. Primary endpoint: All-cause explantation of the breast implant within 180 days after breast reconstruction surgery. Started Jul 2020; status: active.
02
Drugs
cefazolingentamicinvancomycin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-002459-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002459-40.